Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M).

Chounta V, Overton ET, Mills A, et al. Patient. 2021;14(6):849-862.

New York State Department of Health AIDS Institute Clinical Guidelines. In: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults.

McGowan JP, Fine SM, et al. Baltimore, MD: Johns Hopkins University; 2021.

Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Curr Opin HIV AIDS. 2022;17(1):15-21.

Lenacapavir as part of a combination regimen in treatment-naïve PWH [people with HIV]: week 54 results.

Gupta SK, Sims J, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infection. February 12-16, 2022. Abstract 138.

Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.

Howe ZW, Norman S, Lueken AF, et al. Pharmacotherapy. 2021;41(8):686-699.

Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.

Kerrigan D, Mantsios A, Gorgolas M, et al. PLoS One. 2018;13(1):e0190487.

Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials.

Mantsios A, Murray M, Karver TS, et al. AIDS Behav. 2020;24(12):3473-3481.

Long-acting lenacapavir in people with multidrug resistant HIV-1: week 52 results.

Ogbuagu O, Segal-Maurer S, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; virtual conference. Abstract 491.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.

The promise of improved adherence with long-acting antiretroviral therapy: what are the data?

Scarsi KK, Swindells S. J Int Assoc Provid AIDS Care. 2021;20:23259582211009011.

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.